| Role of receptor tyrosine kinases in gastric cancer： New targets for a selective therapy |
| |
| 引用本文： | Becker JC,Muller-Tidow C,Serve H,Domschke W,Pohle T. Role of receptor tyrosine kinases in gastric cancer： New targets for a selective therapy[J]. World journal of gastroenterology : WJG, 2006, 12(21): 3297-3305. DOI: 10.3748/wjg.v12.i21.3297 |
| |
| 作者姓名： | Becker JC Muller-Tidow C Serve H Domschke W Pohle T |
| |
| 作者单位： | [1]Department of Medicine B,University of Münster, D-48129 Münster, Germany [2]Department of Medicine A, University of Münster, D-48129 Münster, Germany |
| |
| 基金项目： | Innovative,Medical,Research,fund,University,of,Münster,,Germany(项目编号：PO210205) |
| |
| 摘 要： | Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success.
|
| 关 键 词： | 受体 酪氨酸激酶 胃癌 治疗方法 |
| 收稿时间： | 2006-01-23 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy |
| |
| Becker J C,Muller-Tidow C,Serve H,Domschke W,Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy[J]. World journal of gastroenterology : WJG, 2006, 12(21): 3297-3305. DOI: 10.3748/wjg.v12.i21.3297 |
| |
| Authors: | Becker J C Muller-Tidow C Serve H Domschke W Pohle T |
| |
| Affiliation: | 1. Department of Medicine B, University of Münster, D-48129 Münster, Germany
2. Department of Medicine A, University of Münster, D-48129 Münster, Germany |
| |
| Abstract: | Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success. |
| |
| Keywords: | Gastric carcinoma EGFR Gefitinib Trastuzumab Cetuximab Imatinib Erlotinib Bevacizumab |
| 本文献已被 维普 万方数据 PubMed 等数据库收录！ |
|
